Drug intelligence / Profile preview

Lifei

Development stage: Unknown
Lead developer: Jilin Fukang Pharmaceutical
Administration: Oral

Overview

Lifei (also known as Lifei Pian or Lifei Tablets) is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Jilin Fukang Pharmaceutical. It is primarily indicated for the treatment of respiratory and lung-related conditions, including chronic bronchitis, asthma, and cough associated with lung deficiency or phlegm-heat. The formulation is designed to 'moisten the lungs,' resolve phlegm, and suppress cough through the synergistic effects of its multiple herbal and animal-derived components. Common ingredients in this formulation typically include *Radix Stemonae*, *Radix Peucedani*, *Folium Eriobotryae*, *Gekko gecko*, and *Radix Glycyrrhizae*. Lifei is administered orally as a tablet and is currently approved and marketed in China.

Brand names: Lifei TabletsLifei Pian
Other names: 利肺片

Beyond the preview

Go deeper on Lifei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lifei.

Explore the full profile